Thus, panobinostat is postulated to induce anti-tumor immunity on the level of bulk tumor, whereas venetoclax/anti-CD40 induces anti-tumor immunity on the level of resistant, tumor-initiating CSCs. The gene discussed is CD40; the disease is neoplasm.